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High-throughput and automated 
diagnosis of antimicrobial 
resistance using a cost-effective 
cellphone-based micro-plate reader
Steve Feng1,2, Derek Tseng1,2, Dino Di Carlo2,3,4, Omai B. Garner5 & Aydogan Ozcan1,2,3,6
Routine antimicrobial susceptibility testing (AST) can prevent deaths due to bacteria and reduce the 
spread of multi-drug-resistance, but cannot be regularly performed in resource-limited-settings due to 
technological challenges, high-costs, and lack of trained professionals. We demonstrate an automated 
and cost-effective cellphone-based 96-well microtiter-plate (MTP) reader, capable of performing AST 
without the need for trained diagnosticians. Our system includes a 3D-printed smartphone attachment 
that holds and illuminates the MTP using a light-emitting-diode array. An inexpensive optical fiber-
array enables the capture of the transmitted light of each well through the smartphone camera. A 
custom-designed application sends the captured image to a server to automatically determine well-
turbidity, with results returned to the smartphone in ~1 minute. We tested this mobile-reader using 
MTPs prepared with 17 antibiotics targeting Gram-negative bacteria on clinical isolates of Klebsiella 
pneumoniae, containing highly-resistant antimicrobial profiles. Using 78 patient isolate test-plates, 
we demonstrated that our mobile-reader meets the FDA-defined AST criteria, with a well-turbidity 
detection accuracy of 98.21%, minimum-inhibitory-concentration accuracy of 95.12%, and a drug-
susceptibility interpretation accuracy of 99.23%, with no very major errors. This mobile-reader could 
eliminate the need for trained diagnosticians to perform AST, reduce the cost-barrier for routine 
testing, and assist in spatio-temporal tracking of bacterial resistance.
The increasing prevalence of antimicrobial resistance represents a severe threat to global health1,2 and is becoming 
more common to bacterial pathogens in high mortality diseases including pneumonia3, diarrheal disease4, and 
sepsis5. Part of the global challenge in combating these organisms is that routine antimicrobial susceptibility testing 
(AST) is not often performed due to technological challenges, high costs, and lack of professional training, which 
greatly contributes to high mortality and the global spread of multi-drug resistant organisms6–10. The goals of anti-
microbial susceptibility testing include the detection of possible drug resistance and assurance of susceptibility 
to drugs of choice for each particular infection.
The gold standard for antimicrobial susceptibility testing is the broth microdilution method11. This procedure 
involves preparing two-fold dilutions of antibiotics in a liquid growth medium that is dispensed in a 96-well 
microtiter plate (MTP), with plates typically prepared for standard bacterial groups (e.g., Gram-negative or 
Gram-positive). The antibiotic containing wells are inoculated with a standardized bacterial suspension with 
bacteria isolated from a patient. Following overnight incubation, the tubes are examined by trained experts for 
visible growth as evidenced by turbidity (see Fig. 1a,c). The lowest concentration of antibiotic that prevented 
growth represents the minimum inhibitory concentration (MIC). This is a quantitative result that allows tracking 
of resistance. The MIC value must be interpreted using a table of values that relate to the proven clinical efficacy 
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of each antibiotic for various bacterial species. An interpretive criterion (e.g., susceptible or resistant) is assigned 
to each bacteria/drug combination in order to guide the physician in treatment decisions. These interpretive cri-
teria have been established by both the U.S. Food and Drug Administration (FDA) and the Clinical Laboratory 
Standards Institute (CLSI) using data from animal studies, microbiological studies, and clinical efficacy data. A 
susceptible result indicates that the patient’s organism should respond to therapy, while a resistant organism will 
not be inhibited by the concentrations of antibiotic achieved with normal dosages used for that drug.
An important part of the global challenge for this gold standard testing is that a high level of clinical microbi-
ology expertise and tedious examination of the well plate is required to read the turbidity from the MTP and to 
establish the interpretive criteria necessary for treatment. An additional global challenge is that the data collected 
in clinical microbiology laboratories are not easily available for epidemiological studies, and are not available at 
all in regions of the world where antimicrobial susceptibility testing is not regularly performed.
Over the past several years, smartphones and other portable consumer electronics devices have demonstrated 
their capability for serving as a multiplexed platform for building biomedical imaging, sensing and diagnostic 
systems12–42. These portable measurement tools typically utilize opto-mechanical attachments used in conjunc-
tion with the built-in capabilities of the mobile device (e.g., camera, microphone, GPS) to provide cost-effective, 
rapid, portable, and highly distributable imaging and sensing systems. As an example, we previously developed 
a cellphone-based 96-well microplate reader for analyzing enzyme-linked immunosorbent assays (ELISA) and 
demonstrated its capability for reading and quantification of various FDA-approved colorimetric ELISA tests 
including e.g., mumps IgG, measles IgG, and herpes simplex virus IgG29. Using the same opto-mechanical hard-
ware attachment to a mobile phone and a new custom-designed smart application and computational approach, 
here we report a new cellphone-based antimicrobial susceptibility testing system that can serve as a cost-effective, 
hand-held, and automated turbidity reader for rapid quantification and analysis of micro-well susceptibility 
results (see Fig. 2). This AST system is composed of a smartphone (Nokia Lumia 1020) that is paired with a 3D 
printed portable opto-mechanical attachment and a data processing server (e.g., a laptop or a PC) in communica-
tion with a Windows Phone based mobile application that serves as an interactive graphical user interface (GUI). 
After inserting an antimicrobial susceptibility test plate into the attachment, the phone’s camera application is 
used to capture the transmitted light from each well in the MTP at multiple exposures (see Fig. 1b,d), and then 
our app uploads these images to a local or remote server to automatically quantify well turbidity. By selecting the 
Figure 1. Comparison of existing method of diagnosis and our method. (a) Current diagnosis method 
consists of diagnosticians manually inspecting plates under a light source to identify well turbidity as a sign of 
microbial growth. In this case, a mirror is used to provide ease of viewing the plate. (b) When using our system, 
a lab technician untrained in plate diagnosis will only need to take three images of each plate and upload the 
captured images using our application to a local or remote server for automated processing to obtain equivalent 
diagnostic results. (c) A close-up of the mirrored image. Here wells B1, C1, D1, B6, B7, and H11 contain 
turbidity. (d) The same plate as imaged using our system. The presence of turbidity in each well is automatically 
determined based off the measured transmittance of light through the well.
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drug target type of the treated plate (e.g., Gram-negative or Gram-positive) and the microbe of interest, the server 
then determines the drug-specific MIC and corresponding interpretive criteria and returns the results to the user 
through the same mobile application within 1 minute.
We demonstrated this mobile system’s ability to automatically determine drug-specific MIC and correspond-
ing drug resistance through a comprehensive clinical evaluation performed at the UCLA Clinical Microbiology 
Laboratory using plates containing 17 different antibiotics targeted for Gram-negative bacteria and tested on 
patient isolates of Klebsiella pneumoniae. This species of bacteria can exhibit highly resistant antimicrobial pro-
files and contain members of the Carbapenem resistant Enterobacteriaceae (CRE), with a very high mortality rate 
in multiple disease states including sepsis and pneumonia43–50. CRE have complicated antimicrobial resistance 
profiles and represent a significant challenge to global health. Our mobile AST reader’s performance exceeds 
the FDA defined criteria for susceptibility testing51 with an MIC agreement of > 95% with no very major errors 
(i.e., resistant microbes misdiagnosed as susceptible), 0.16% major errors (i.e., susceptible microbes misdiagnosed 
as resistant), and 0.65% minor errors (i.e., indeterminate/susceptible dose dependent-related misdiagnoses).
Methods
System Design. Our AST system (Fig. 2) is comprised of a Windows Phone-based smartphone used to 
capture images of the MTP, held within a 3D-printed attachment including optical components for illuminating 
the MTP, and a local or remote server for rapidly processing and interpreting the plate images uploaded through a 
custom-designed application running on the same smartphone. While our current prototype is based on a Nokia 
Lumia phone, this platform can also be used with iOS and Android based smartphones with minor modifications 
to its design. Figure 2a provides a cross-section of our 3D printed device, with the cellphone placed at the top, 
next to six AAA batteries, which power an array of 24 uniformly distributed light-emitting-diodes (LEDs, at 
464 nm) through a low-noise, low-dropout linear current regulator to prevent power fluctuations and maintain 
constant illumination of the AST plate29. To maximize the spatial uniformity of the illumination, each LED is 
centered between 4 wells and placed above two layers of optical diffusers to homogenize the illumination. When 
testing a new plate, the MTP is inserted into a fitted space below the LED array, with an inexpensive plastic-based 
fiber-optic bundle coupling the blue LED light that is transmitted through each well to an external lens (focal 
length 45 mm) placed in front of the cellphone camera. The smartphone’s camera application is used to obtain raw 
10-bit Digital Negative (DNG) format images of the fiber bundle as seen in Fig. 1d. This unique instrument design 
involving a fiber-optic array that is mapped to individual wells of a plate provides a significantly more compact 
and light-weight AST platform without suffering from optical aberrations since the 96-well plate is transformed 
into an imaging area at the end of the fiber bundle that is more than two orders of magnitude smaller compared 
to the actual area of the well plate. Bending induced losses in each fiber optic cable can create well-to-well signal 
variations, all of which have been calibrated out after the assembly of the fiber-optic array by using blank plates. 
The overall dimensions of this hand-held AST reader are ~195 × 98 × 100 mm (see Fig. 2) and it weighs ~0.62 kg. 
All the components of our opto-mechanical attachment to the smartphone would cost ~100 USD in total, even at 
very low production volumes. An automated AST platform, on the other hand, typically costs significantly more 
Figure 2. Portable 96-well microtiter plate turbidity reader for antimicrobial susceptibility testing. (a) Our 
device consists of a custom-design hardware attachment for the Nokia Lumia 1020 smartphone, using an LED 
array through a diffuser to illuminate 96-well plates, which are optically transmitted through an optical fibre 
bundle to a small region of interest, imaged through the smartphone’s built-in camera module with the addition 
of a focusing lens. (b) Top view of our device. (c) Side view of our device.
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(e.g., ~$30,000) and would be much larger and heavier compared to our hand-held platform, although it would 
also perform other AST related functions including e.g., the Kirby-Bauer Disk diffusion interpretation, among 
other automated tasks that we do not perform in our mobile platform.
Image Analysis for AST. Figure 3 illustrates the communication between our smartphone application and 
the data processing server, which is also used for spatio-temporal tagging and storage of our results. After insert-
ing a new AST plate into the attachment, images are captured using the mobile phone’s camera application at three 
different exposure times (dim: 1/1600 sec, moderate: 1/1250 sec, and bright: 1/800 sec) and saved as 10-bit DNG 
images. These 10-bit DNG images represent the best possible image quality obtainable on this mobile platform, 
with the other alternative being compressed JPEG format with 8-bit images. From the main menu (see Fig. 4a), 
the user starts a new test analysis and first selects the three images previously captured to be used for processing 
(see Fig. 4b). Next, the user selects whether the plate type is Gram-negative or Gram-positive and then uses the 
search box to find the bacterium to-be-tested, such that the server knows which wells correspond to which drugs 
and how to analyse the MIC and perform automated drug susceptibility interpretation, respectively. By clicking 
“submit”, the images, plate type, and bacterium to-be-tested are sent to a local or remote server for processing.
On receiving a new request, the server (implemented in Python using the Twisted framework) adds the 
request to the job queue and saves the images and job details to local storage. Each DNG image is converted into 
16-bit tagged image file format (TIFF) and the pixels corresponding to the blue channel are extracted from the 
raw Bayer image. Subsequent processing of the blue channel images is performed using MATLAB. The server also 
has pre-recorded information of the mapping between the fiber-optic cables of our AST device and the individual 
wells of a 96-well plate. This 2D mapping does not change from image to image, and only needs to be determined 
once for a given device design. To find this mapping function, a bright-field image (i.e., a control image) of a plate 
is taken with deionized (DI) water with no turbidity in the wells and the centre of each fiber-optic cable is digi-
tally calculated. To map successive images of the AST plates to this control image, corner wells are found using a 
threshold-based approach followed by morphological operations to separate adjacent wells. The corner wells are 
then used to remove scaling and alignment issues that might be caused by the camera’s auto-focus feature and 
potential misalignments between the camera and fiber-optic array, where the known physical distances among 
the fiber-optic cables are exploited to find the centre of each well. A circular mask with a radius of 25 pixels is then 
applied to reduce the interference from nearby fiber-optic cables before extracting the average intensity of each 
well’s signal.
After extracting each well’s pixel intensity, the average intensities per well for the dim, moderate, and bright 
images are each normalized with respect to the average intensities of control images at each exposure time to scale 
Figure 3. Overview of client-server communication and image analysis. Using our custom-developed 
mobile application, three images of the sample plate taken at different exposure times are uploaded to our local 
or remote server. Our automated algorithm finds the wells using the blue channel of the brightest exposure 
image and extracts the average well intensity. The well intensities for the three exposures are then combined 
to maximize the dynamic range of our measured intensities and normalized respective to the maximum 
transmittance as obtained from blank plate control wells. These well intensities are then thresholded based off 
a database of uploaded plates and processed to determine each drug’s minimum inhibitory concentration and 
susceptibility. These results are stored on the server along with the uploaded plate images, and also returned to 
the client application to be shown to the user.
www.nature.com/scientificreports/
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the intensities from 0 to 1, with 1 representing complete transmittance of light through the well relative to the DI 
control. To maximize our dynamic range, the normalized transmittance values for each well from the dim, mod-
erate, and bright images are first scaled respective to their integration times and then averaged to obtain a single 
higher dynamic range value for each well.
To determine whether a well contains turbidity or not, we use a threshold-based approach to determine the 
cut-off transmittance value for each well. To choose an accurate threshold value for each well, we extract the nor-
malized transmittance values of wells with no turbidity from a training set of patient plates and blank reference 
plates (i.e., plates with drugs but no microbes). As the turbidity increases, the light transmittance through the well 
decreases. Thus, from this set of normalized transmittance values from wells with no turbidity, for each well we 
decided to use a threshold at two times the standard deviation below the mean to determine whether a given well 
is statically likely to have microbial growth represented by turbidity. For a given plate type (i.e., Gram-negative or 
Gram-positive), the MIC for each drug is determined by finding the first well in each drug-specific set of wells that 
contains turbidity. Depending on the selected microbe of interest, drug susceptibility interpretations are auto-
matically made based on the MIC for each drug (see Supplementary Table 1 for an example chart for Klebsiella 
pneumoniae).
After the turbidity decisions of the wells, the MIC determination, and the drug susceptibility interpreta-
tions are all automatically made, the results are stored in a database on the server, and are also sent back to the 
Figure 4. Screenshots of our custom Windows Phone application for uploading images of well plates 
and displaying processed results. (a) From the main menu, users can submit a new test or review previously 
submitted tests. (b) After starting a new test, users select and upload three DNG format images of the 96-
well plate captured at 3 different exposures. (c) Users next select the type of plate to be processed and choose 
the microbe to-be-tested. A search bar facilitates the selection process, after which users select the specific 
microbe. Clicking the “submit” button sends the plate type, microbe, and images to a local or remote server 
for processing. (d) Processed results can be reviewed through a history listing based off the time of upload 
and plate type. (e,f) Plate analysis returns the minimum inhibitory concentration and the corresponding drug 
susceptibility diagnosis for the specified plate type in a scrollable table. The turbidity detection for each well can 
also be viewed in a colored table, with red rectangles indicating no turbidity and green-yellow ovals indicating 
wells with turbidity.
www.nature.com/scientificreports/
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originating smartphone within 1 minute. On the smartphone application, the user can review the results via the 
history page (see Fig. 4d), which lists all the uploaded tests and the microbes tested for. After clicking on a test, 
the user can view the susceptibility results in a scrollable table (see Fig. 4e), with the drug or drug combination 
in the first column, the MIC in the second column, and the susceptibility interpretation in the third column. The 
user can also swipe the page to see the detection of well turbidity in a color-coded table format (see Fig. 4f), with 
red coloured rectangles indicating no turbidity and green-yellow coloured ovals indicating the wells that contain 
turbidity.
Design of Clinical Testing. We tested our platform using Klebsiella pneumonia isolates from patient samples 
collected by the UCLA hospital system and prepared and tested at the UCLA Clinical Microbiology Laboratory. 
Antimicrobial agents are tested using two-fold serial dilutions and the concentration range varies with the drug, 
the organism tested, and the site of the infection. For the microdilution method, the antimicrobial dilutions are 
in 0.1 mL volumes that are contained in wells of a 96 well microdilution tray. The drug panels are then stored 
frozen until they are inoculated. Briefly, a suspension of the tested organism is prepared in sterile saline to a 0.5 
McFarland standard using isolated colonies. 1.5 mL of the suspension is transferred to an inoculating tray con-
taining 40 mL of sterile distilled water. The inoculating tray has prongs that allow for transfer of bacteria into each 
well of the 96 well drug plate. The plate is then incubated for 24 hours at 37 °C. The panels are quality controlled 
with the appropriate ATCC (American Type Culture Collection) organisms. The bacterial pathogen identification 
was performed after the culture of the organism by MALDI-TOF (matrix assisted laser desorption/ionization - 
time of flight) identification method. For each plate, an expert diagnostician inspected the plate and recorded the 
presence or absence of turbidity in each well, which was used as our gold standard. Each plate was then imaged 
using our smartphone-based platform. All experiments were conducted at the UCLA Clinical Microbiology 
Laboratory by a medical personnel trained on how to use the mobile platform. This study was found to be exempt 
from IRB (Institutional Review Board) review by the UCLA Office of the Human Research Protection Program.
Calculation of MIC and Drug Susceptibility Interpretation. The MIC and drug susceptibility for 
Klebsiella pneumoniae were determined using a chart provided by the UCLA Clinical Microbiology Laboratory 
(see Supplementary Table 1). For each drug, the MIC is determined by finding the first well with turbidity for 
increasing drug concentration and the susceptibility determined using a look-up table.
Results
We validated the capability of our cellphone-based AST system to perform highly accurate MIC determination 
and drug susceptibility interpretation, greatly exceeding the FDA-defined criteria for susceptibility testing, with 
clinical isolates of the Gram-negative bacterium Klebsiella pneumoniae. Table 1 shows the mean and standard 
deviation for well turbidity detection accuracy, well turbidity detection sensitivity, well turbidity detection speci-
ficity, MIC determination accuracy, and drug susceptibility interpretation accuracy of our AST reader when using 
only the best performing single exposure image (i.e., bright exposure) and when combining the dim, moderate, 
and bright exposure images to digitally increase the dynamic range. In these trials, 39 randomly chosen patient 
isolate plates and 21 blank plates without microbial content were used to determine an optimal threshold for well 
turbidity detection, followed by a blind-test on the remaining 39 patient isolate plates, none of which were used in 
our training. Blank plates were included in the training set since some wells always exhibit bacterial growth due 
to high antimicrobial resistance. This training and blind-testing process was performed 50 times with random 
sampling of patient plates to generate the standard deviations. As can be seen from this table, combining multiple 
image exposures significantly increases the overall accuracy of AST using our system and reduces variability for 
well turbidity detection, with significant improvements for MIC determination and drug susceptibility interpre-
tation. Based on these results, we achieved an average well turbidity detection accuracy of 98.21%, a minimum 
Images used Well Accuracy Well Sensitivity Well Specificity MIC Accuracy
Drug Susceptibility 
Accuracy
Very Major Error 
Percentage
Major Error 
Percentage
Minor Error 
Percentage
(a) Single exposure 
(1/800) 96.94 ± 1.30% 98.83 ± 0.70% 96.24 ± 1.92% 94.89 ± 1.14% 98.55 ± 0.58% 0.43 ± 0.68% 0.17 ± 0.13% 1.23 ± 0.54%
(b) Combination 
of three exposures 
(1/1600, 1/1250, 1/800)
98.21 ± 0.29% 98.56 ± 0.37% 98.08 ± 0.37% 95.12 ± 0.87% 99.23 ± 0.23% 0 ± 0% 0.16 ± 0.18% 0.65 ± 0.20%
Table 1.  Random sub-sampling validation results averaged over 50 trials, for well turbidity analysis 
and subsequent determination of MIC and microbial drug susceptibility with very major (i.e., resistant 
microbes diagnosed as susceptible), major (i.e., susceptible microbes diagnosed as resistant), and minor 
(i.e., indeterminate/susceptible dose dependent-related misdiagnoses) error percentages for our algorithm 
using (a) a single exposure image and (b) a combination of three exposures. 78 patient isolate testing plates 
from the UCLA Hospital Microbiology Lab and 21 blank plates without microbial content were randomly 
separated 50 times into training sets of 21 blank plates and 39 patient plates and blind-test sets of 39 patient 
plates. The threshold is determined using the training set and run on the corresponding test set, with mean and 
standard deviation across the 50 trials shown in the table. Combining multiple image exposures significantly 
increases the overall accuracy and reduces the variability for well turbidity detection, with corresponding 
improvements for MIC determination and drug susceptibility interpretation as well as significant reductions for 
very major, major, and minor errors.
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inhibitory concentration accuracy of 95.12%, and a drug susceptibility interpretation accuracy of 99.23%, with no 
very major errors (i.e., resistant misdiagnosed as susceptible), 0.16% major errors (i.e., susceptible misdiagnosed 
as resistant), and 0.65% minor errors (i.e., indeterminate/susceptible dose dependent-related misdiagnoses). To 
provide a reference frame for these numbers, our total ground truth dataset across 78 patient plates contains 
960 susceptible decisions, 288 resistant decisions, 70 indeterminate decisions, and 8 susceptible dose dependent 
decisions.
To better explore potential drug susceptibility misdiagnoses using our system, Table 2 shows the spe-
cific results for one training/test set of the multiple exposure results used in the statistical average reported 
in Table 1. Due to the design of the Gram-negative MTP used by UCLA Clinical Microbiology Laboratory 
(see Supplementary Table 1), only 95 wells are used per plate, with 1 well used as a positive control, 1 well 
used as a positive dye, and the remaining 93 wells used for drug testing, which provides us a total of 3705 
turbidity-assessable wells across 39 patient isolate test plates used in our blind testing. These wells are used to 
test 17 drugs and drug combinations per MTP (see Supplementary Table 2 for a list of all the drugs used in our 
experiments) for a total of 663 MIC determinations and drug susceptibility interpretations. We note that in this 
particular example reported in Table 2, the automated turbidity detection and corresponding MIC and drug 
susceptibility accuracy (see Table 2) performed similarly to the average system performance exhibited in Table 1. 
Additionally, this example reported in Table 2 reveals that there are no very major errors (i.e., no resistant bacteria 
misdiagnosed as susceptible) and only 1 major error (i.e., ~0.2% susceptible bacteria misdiagnosed as resistant) 
and 2 minor errors (i.e., ~0.3% indeterminate/susceptible dose dependent-related misdiagnoses) out of a total of 
663 MIC and drug susceptibility interpretations across 39 patient test plates (see Table 2), with no error occurring 
twice on the same plate or for the same drug, exceeding the FDA criteria for clinical susceptibility testing.
Discussion
We demonstrated a cost-effective portable system composed of a mobile phone and a 3D printed opto-mechanical 
attachment that can replace an expert diagnostician with a lab technician trained in the usage of this device 
for interpreting 96-well microtiter plates for antimicrobial susceptibility testing. This mobile platform achieved 
95.12% MIC determination accuracy and 99.23% drug susceptibility interpretation accuracy for Klebsiella pneu-
monia susceptibility testing, exceeding the FDA criteria for performing AST analysis. Since well turbidity pre-
sents similar optical characteristics, adding the ability to test other plate types and microbes can be as simple as 
updating the server logic with the drug series information and drug-microbe susceptibility interpretation as per 
Supplementary Table 1, allowing this platform to easily scale to test other bacteria.
One limitation of this technology remains the need for preparation of the 96-well microtiter plate, which 
typically requires a large machine to deposit specific drug concentrations in each well and fill each well with the 
microbes to-be-tested, extracted from a patient. Regardless, this technology is especially useful in resource-limited 
settings given its ability to remove the need for a trained diagnostician, enabling local technicians to easily be able 
to conduct high-throughput antimicrobial susceptibility testing. In fact, clinical microbiology is rapidly progress-
ing toward automation. Multiple platforms are now available for automated organism identification including 
smart incubators and MALDI-TOF based proteomic identification. Our results and the demonstrated platform 
(A) System Performance
Well Accuracy 98.25%
Well Sensitivity 98.27%
Well Specificity 98.23%
MIC Accuracy 95.32%
Drug Susceptibility Accuracy 99.55%
Very Major Error Percentage 0%
Major Error Percentage 0.21%
Minor Error Percentage 0.30%
(B) Drug Susceptibility Misdiagnoses
Plate ID Drug Automated System Decision Diagnostician Decision Error Type
1 AM Resistant Indeterminate Minor
5 A/S Resistant Indeterminate Minor
8 MPM Resistant Susceptible Major
Table 2.  Trial results from using a training set of 21 blank plates and randomly chosen set of 39 patient 
isolate sample plates and blind-test set of remaining 39 samples from a total of 78 Klebsiella pneumoniae 
patient isolate plates. There are 95 applicable wells per plate, with 1 well used as a positive control, 1 well as 
a positive dye, and the remaining 93 wells for drug testing, yielding a total of 39 × 95 = 3705 applicable wells 
assessed for turbidity. Each plate tests 17 different drugs and drug combinations for a total of 663 MIC and 
drug susceptibility decisions. As highlighted in our System Performance summary (A), well turbidity, MIC 
and drug susceptibility decisions are all comparable to the average performance of our system reported in 
Table 1. The three specific drug susceptibility misdiagnoses reported in (B) (i.e., plates 1, 5 and 8) are all low-risk 
misdiagnoses, with 1 major error and 2 minor errors but no very major errors. None of these are for the same 
drug or plate.
www.nature.com/scientificreports/
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fit very well into future clinical microbiology diagnostic labs, where the gold standard for AST testing and broth 
microdilution can be automated for turbidity reading, MIC interpretation, and appropriate antibiotic prescrip-
tion. Furthermore, paired with the smartphone’s wireless connectivity and inherent digital record-saving, this 
platform can enable widespread and easy collection of drug resistance profiles for spatio-temporal tracking, 
which could be especially useful for isolating and eliminating drug resistant strains of harmful microbials. An 
additional advantage of this technology is the possibility of examining turbidity or bacterial growth in the pres-
ence of a drug at an earlier time point than is currently read (24 hours). Optical analysis by the digital reader may 
potentially reveal early turbidity and allow for a more rapid turn-around time of the AST results to the physician.
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